Reviewing Health Catalyst (NASDAQ:HCAT) and Aclarion (NASDAQ:ACONW)

Aclarion (NASDAQ:ACONW) and Health Catalyst (NASDAQ:HCAT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Valuation and Earnings

This table compares Aclarion and Health Catalyst”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$83,769.00	N/A	N/A	N/A	N/A
Health Catalyst	$311.14 million	0.38	-$177.97 million	($3.68)	-0.43

Aclarion has higher earnings, but lower revenue than Health Catalyst.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aclarion and Health Catalyst, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	0	0	0	0	0.00
Health Catalyst	1	9	3	0	2.15

Health Catalyst has a consensus target price of $2.82, indicating a potential upside of 78.65%. Given Health Catalyst’s stronger consensus rating and higher possible upside, analysts plainly believe Health Catalyst is more favorable than Aclarion.

Profitability

This table compares Aclarion and Health Catalyst’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	N/A	N/A	N/A
Health Catalyst	-90.61%	-1.83%	-0.80%

Insider and Institutional Ownership

85.0% of Health Catalyst shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Health Catalyst beats Aclarion on 6 of the 9 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Health Catalyst

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.